Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Operating Income
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating income?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — operating income of -$3.07M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating income changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating income decreased by 182.0% year-over-year, from $3.74M to -$3.07M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating income?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating income has grown at a -10.5% compound annual growth rate (CAGR), from $24.95M to $19.99M.
- What does gyre pharmaceuticals — operating income mean?
- This measures the profitability of the business segment by subtracting operating expenses and cost of goods sold from total revenue. It is the key metric for evaluating the core operational viability and financial health of the segment independent of financing or tax structures.